Clinical Scorecard: Prostate Screening Rivals Mammography

At a Glance

Key Highlights

• PROBASE trial shows PSA testing followed by MRI and biopsy can match mammography outcomes.
• Biopsy positive predictive value for prostate cancer is 50-68%, significantly higher than 15% for breast cancer.
• False-positive rates in prostate screening are 37-42%, compared to 10% in mammography.
• 69-74% of detected prostate cancers are invasive or high-grade.
• Active surveillance for low-risk disease reduces overtreatment.

Guideline-Based Recommendations

Diagnosis

• Use baseline PSA testing to identify men for further MRI and biopsy.

Management

• Implement active surveillance for low-risk prostate cancer.

Monitoring & Follow-up

• Conduct repeat PSA testing at longer intervals for men with lower PSA levels.

Risks

• Monitor for false-positive results and potential overtreatment.

Patient & Prescribing Data

Men participating in organized prostate cancer screening.

Integrated pathways combining biomarkers and imaging enhance screening efficacy.

Clinical Best Practices

• Adopt risk-adapted screening strategies to minimize overdiagnosis.
• Utilize MRI and targeted biopsy for men with elevated PSA levels.

References

• European Association of Urology Congress